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Epstein - Barr virus (EBV) is a gamma - herpes virus that
infects more 90% of humans. Most EBV primary infections
and reactivations are subclinical and require no therapy in
immunocompetent people. However, EBV infection or
reactivation may result in life-threatening diseases in
immunocompromised people [1-5]. EBV infection and
reactivation might be associated with a spectrum of clini-
cal presentations ranging from fever to post-transplant
lymphoproliferative diseases (PTLD), including viremia,
pneumonia, encephalitis/ myelitis, PTLD, and so on, in
recipients of allogeneic hematopoietic stem cell transplan-
tation (allo-HSCT), which arise as a consequence of
infected B/T lymphocytes, epithelial cells and neural cells,
a n dt h e ya r es u s t a i n e db yE B Vl a t e n c yp r o d u c t s[ 2 , 3 , 6 ] .
EBV-associated PTLD were only the tip of the iceberg of
post-transplant EBV-associated diseases [2], but there is
short of large sample data about the incidence of EBV-
associated other diseases other than PTLD in recipients of
transplants. Kinch et al. reported that 7 of 16 patients with
EBV-DNA-emia developed EBV-associated diseases in 39
recipients of allo-HSCT, including 3 PTLD, 1 myelitis,
1 encephalitis and 2 reactivations with fever [7]. In one of
our prospective study, 16 of 64 patients with EBV-DNA-
emia developed PTLD and 11 patients developed EBV-
associated other diseases, including 6 fever, 1 encephalitis,
1 myelitis, 1 pneumonia, 1 encephalitis accompanying
pneumonia and 1 enteritis accompanying hepatitis, in 172
recipients of allo-HSCT. The incidence of PTLD in a large
study varied from 0.5% to 22% after allo-HSCT, depending
on the number of risk factors including T-depleted graft,
the use of ATG, unrelated donor, HLA- mismatched,
acute / chronic graft versus host disease (GVHD), cytome-
gavirus (CMV) antigen-emia, and so on [3,8,9]. Except for
lymph nodes, EBV can also involve nearly all other tissues
and organs in recipients of transplants, and isolated central
nervous system (CNS) involvement with PTLD is consid-
ered to be an exceedingly rare complication after allo-
HSCT [10]. But our prospective study showed that 16 of
27 patients with EBV-associated diseases were extranodal
involvement and 12 patients developed EBV-associated
CNS diseases (6 CNS-PTLD, 5 encephalitis and 1
myelitis).
According to the data of the European Group for Blood
and Marrow Transplantation (EBMT) [11], RQ-PCR mon-
itoring of EBV-DNA of blood in 73% transplant center has
become a routine method for identifying HSCT recipients
at risk for developing EBV-associated disease, diagnosis,
preemptive therapy and therapeutic evaluation. EBV-DNA
loads of blood are acted as the main basis for diagnosis,
preemptive therapy and therapeutic evaluation, but our
study and others cases reports [12,13] showed that special
EBV-associated disease in CNS and pulmonary had the
discrepancy in EBV-DNA loads; sometimes repeated test-
ing with real-time PCR in peripheral blood failed to show
any evidence of EBV reactivation, and the change of EBV-
DNA loads of blood was inconsistent with disease devel-
opment. But frequent quantitative monitoring of EBV viral
load in high-risk patients is still important to prevent
occurrence of EBV-PTLD [14].
Important issues of low morbidity and mortality of
EBV-associated disease is restoring the immune response
to EBV. Therefore, one of prevention and therapeutic
option is to manipulate the immune system to target and
eradicate these malignancies. In recipients of allo-HSCT
in particular, these strategies aim to tilt the balance
toward EBV immune responses either by depleting the
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any medium, provided the original work is properly cited.B-cell population (including EBV-infected B cells) or by
augmenting the cellular immune response to EBV. The
patients with high risk EBV-DNA-emia are advocated to
perform preemptive therapy. Rituximab (anti-CD20) has
been applied widely as first-line drug of preemptive ther-
apy. The treatment of EBV-associated diseases include
rituximab (AII), reducing immunosuppression (BII),
donor lymphocyte infusion (DLI) (CIII) and donor EBV-
specific cytotoxic T cells (CTL) infusion (CII), and che-
motherapy (CIII). Antiviral agents (EIII) and intravenous
immune globulin (IGIV) (DIII) are not recommended for
PTLD [5]. Rituximab has dramatically decreased EBV-
PTLD incidence and leads to better overall survival
[15-18]. The initial response rates of administration of
rituximab to EBV-associated diseases ranged from 39.2%
to 100% [5,17,19]. But recently report indicated rituximab
preemptive treatment was associated with high infection
rate and prolonged immune defect [15]. Reducing immu-
nosuppression to restore immune responses to EBV is
usually not a useful approach for treating EBV-associated
diseases early after allo-HSCT, because the patients are
profoundly immunosuppressed and the regenerating
immune system usually cannot recover fast enough to
eradicate the malignant cells, and meanwhile, high risk of
occurrence of GVHD exists. EBV-specific CTL acts as
the best treatment of EBV-associated diseases [20], but
this approach is currently confined to experimental pro-
tocols, and additional drawbacks are the time (2-3
months) and facilities required for CTL production.
Other therapeutic strategies such as DLI, chemotherapy,
or use of antiviral agents have a limited place in the man-
agement of PTLD.
In conclusion, EBV infection or reactivation can pre-
sent as a variety of clinical symptoms and signs, and
involve nearly all tissues and organs in recipients of allo-
HSCT. EBV-associated other diseases (other than PTLD),
especially CNS and pulmonary diseases, were not rare in
recipients of allo-HSCT. EBV-DNA monitoring of blood
was a routine method for diagnosis of PTLD and acted as
an important indicator for preemptive therapy and thera-
peutic evaluation. However, case reports demonstrated
that patients with isolated EBV-associated CNS PTLD
might be the cerebrospinal fluid (CSF) EBV-DNA posi-
tive, but blood EBV-DNA negative. The preemptive use
of rituximab can reduce the risk of death due to EBV-
PTLD in the setting of allo-HSCT. The question of over-
treatment can be raised and further studies are needed to
select candidates for pre-emptive treatment in order to
avoid systematic anti-CD20 treatment and its later poten-
tial complications. The problem in developing a treat-
ment for EBV-associated PTLD is the lack of later-phase
trials from which to develop evidence-based guidelines.
Hopefully, as newer targeted therapies, such as allogeneic
EBV-CTL, and more targeted chemotherapy regimens
are evaluated, more definitive trials to treat EBV lympho-
proliferations will be designed and completed.
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